"Adoptive Transfer" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of passive immunization where previously sensitized immunologic agents (cells or serum) are transferred to non-immune recipients. When transfer of cells is used as a therapy for the treatment of neoplasms, it is called adoptive immunotherapy (IMMUNOTHERAPY, ADOPTIVE).
| Descriptor ID |
D019264
|
| MeSH Number(s) |
E02.095.465.425.400.330.050 E05.478.550.520.050
|
| Concept/Terms |
Adoptive Cell Transfer- Adoptive Cell Transfer
- Adoptive Cell Transfers
- Cell Transfer, Adoptive
- Cell Transfers, Adoptive
|
Below are MeSH descriptors whose meaning is more general than "Adoptive Transfer".
Below are MeSH descriptors whose meaning is more specific than "Adoptive Transfer".
This graph shows the total number of publications written about "Adoptive Transfer" by people in this website by year, and whether "Adoptive Transfer" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 4 | 4 |
| 2000 | 0 | 3 | 3 |
| 2001 | 1 | 5 | 6 |
| 2002 | 0 | 4 | 4 |
| 2003 | 2 | 8 | 10 |
| 2004 | 1 | 8 | 9 |
| 2005 | 0 | 5 | 5 |
| 2006 | 3 | 5 | 8 |
| 2007 | 1 | 4 | 5 |
| 2008 | 0 | 7 | 7 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 4 | 5 |
| 2011 | 0 | 3 | 3 |
| 2012 | 1 | 7 | 8 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 5 | 5 |
| 2015 | 1 | 7 | 8 |
| 2016 | 0 | 6 | 6 |
| 2017 | 1 | 4 | 5 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adoptive Transfer" by people in Profiles.
-
Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma. Oncoimmunology. 2021 05 25; 10(1):1929726.
-
Soluble N-Acetylgalactosamine-Modified Antigens Enhance Hepatocyte-Dependent Antigen Cross-Presentation and Result in Antigen-Specific CD8+ T Cell Tolerance Development. Front Immunol. 2021; 12:555095.
-
Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth. Cancer Immunol Res. 2021 04; 9(4):415-429.
-
Type II Natural Killer T Cells Contribute to Protection Against Systemic Methicillin-Resistant Staphylococcus aureus Infection. Front Immunol. 2020; 11:610010.
-
T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1. Front Immunol. 2020; 11:575977.
-
Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight. 2019 11 01; 4(21).
-
Synthetically glycosylated antigens induce antigen-specific tolerance and prevent the onset of diabetes. Nat Biomed Eng. 2019 10; 3(10):817-829.
-
Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells. Cell. 2019 05 16; 177(5):1172-1186.e14.
-
Allergen Exposure in Lymphopenic Fas-Deficient Mice Results in Persistent Eosinophilia Due to Defects in Resolution of Inflammation. Front Immunol. 2018; 9:2395.
-
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res. 2018 09; 6(9):990-1000.